ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue, Suite 100

Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817


SEARCH JOBS




Collaborations

AVANIR Pharmaceuticals 





 Company News
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Published In The Journal Of Immunology Research Support Phosphatidylserine (PS) As A Potential Target In Ebola Infection 10/15/2014 11:21:18 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Presented At CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance The Anti-Tumor Activity Of Immune Checkpoint Inhibitors By Decreasing Levels Of Myeloid Derived Suppressor Cells (MDSC) In The Tumor Microenvironment 10/6/2014 11:01:06 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 9/10/2014 12:00:46 PM
Peregrine Pharmaceuticals, Inc. (PPHM) Reports First Quarter Fiscal Year 2015 Financial Results And Recent Developments 9/10/2014 11:32:36 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Report First Quarter Fiscal Year 2015 Financial Results After Market Close On September 9, 2014 9/3/2014 2:44:10 PM
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Fourth Quarter And Year-End Fiscal Year 2014 Financial Results And Recent Developments 7/15/2014 11:40:39 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Report Fourth Quarter And Year-End Fiscal 2014 Financial Results After Market On July 14, 2014 7/8/2014 12:35:41 PM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 6/11/2014 9:31:50 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Initiation Of An Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) In Advanced Melanoma 4/23/2014 9:02:14 AM
Data Presented At American Association for Cancer Research Support Potential Of Peregrine Pharmaceuticals, Inc. (PPHM)'s PS-Targeting Immunotherapy Bavituximab To Enhance Anti-Tumor And Immune-Stimulating Effects Of Anti-CTLA-4 And Anti-PD-1 Treatments In Models Of Melanoma And Colon Cancer 4/9/2014 9:53:52 AM
12345678910...